Page last updated: 2024-09-03

vadimezan and Day Blindness

vadimezan has been researched along with Day Blindness in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Acton, G; Baguley, BC; Green, C; Hogg, CR; Jameson, MB; Jeffery, M; McKeage, MJ; Sharp, DM; Sissingh, JI; Thompson, PI; Waller, S	1

Trials

1 trial(s) available for vadimezan and Day Blindness

Article	Year
Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Investigative ophthalmology & visual science, 2009, Volume: 50, Issue:6 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Angiogenesis Inhibitors; Antineoplastic Agents; Color Perception Tests; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Humans; Infusions, Intravenous; Neoplasms; Phosphodiesterase Inhibitors; Retina; Retinal Diseases; Vision Disorders; Visual Acuity; Xanthones	2009

Article

Year

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

Investigative ophthalmology & visual science, 2009, Volume: 50, Issue:6

Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Angiogenesis Inhibitors; Antineoplastic Agents; Color Perception Tests; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Humans; Infusions, Intravenous; Neoplasms; Phosphodiesterase Inhibitors; Retina; Retinal Diseases; Vision Disorders; Visual Acuity; Xanthones

2009